Winston Tan, MD, discusses the emergence of novel agents for the treatment of patients with gastrointestinal stromal tumors, namely agents like avapritinib and ripretinib, which have shown promise in ongoing clinical trials.<br />
Winston Tan, MD, hematologist/oncologist, Mayo Clinic, discusses the emergence of novel agents for the treatment of patients with gastrointestinal stromal tumors (GIST), namely agents like avapritinib (BLU-285) and ripretinib (DCC-2618), which have shown promise in ongoing clinical trials.
Any drug that has the ability to delay progression of disease is a good treatment option, says Tan. It is also important, however, to find the maximum tolerated dose in clinical trials to limit toxicity in patients with GIST. Another important component to clinical trials is molecular testing. Identifying molecular targets and then hitting those targets may help oncologists to control the disease even longer.
Even with the emergence of promising new agents, physicians should not discount the drugs that are already approved for the treatment of locally advanced GIST in the adjuvant setting. The primary drug is imatinib (Gleevec), which works well for patients withc-KIT
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More